Whitford C, Candy J, Edwardson J, Perry R
MRC Neuroendocrinology Unit, Newcastle General Hospital, Newcastle upon Tyne, U.K.
J Neurol Sci. 1988 Aug;86(1):13-8. doi: 10.1016/0022-510x(88)90003-2.
A reduction in the levels of somatostatin-like immunoreactivity (SLI) and somatostatin binding sites in the cerebral cortex has been previously reported to occur in Alzheimer's disease (AD) and Parkinson's disease with associated dementia. In the present study, the levels of both SLI and high affinity [3H]somatostatin binding sites have been measured in the frontal (Brodmann area 9) and temporal (Brodmann area 21) cortices in patients with presenile and senile Alzheimer's disease, and in mentally normal and cognitively impaired cases of Parkinson's disease. The results were compared with those obtained from a group of normal patients matched for age and postmortem delay. No significant changes in SLI or somatostatin binding in the frontal and temporal cortex were found between any of the disease groups. These results suggest that involvement of the somatostatinergic system in AD or Parkinson's disease is not a consistent or primary neurochemical feature of these diseases.
先前有报道称，在患有阿尔茨海默病（AD）以及伴有痴呆的帕金森病患者中，大脑皮质中生长抑素样免疫反应性（SLI）水平和生长抑素结合位点会降低。在本研究中，已对早老性和老年性阿尔茨海默病患者以及帕金森病精神正常和认知受损病例的额叶（布罗德曼第9区）和颞叶（布罗德曼第21区）皮质中的SLI水平和高亲和力[3H]生长抑素结合位点进行了测量。将结果与一组年龄和死后延迟时间相匹配的正常患者的结果进行了比较。在任何疾病组之间，额叶和颞叶皮质中的SLI或生长抑素结合均未发现显著变化。这些结果表明，生长抑素能系统参与AD或帕金森病并非这些疾病一致或主要的神经化学特征。
